EP1740557A1 - Derives d'uree utilises en tant qu'antagonistes du recepteur vanilloide (vr1) - Google Patents

Derives d'uree utilises en tant qu'antagonistes du recepteur vanilloide (vr1)

Info

Publication number
EP1740557A1
EP1740557A1 EP05716548A EP05716548A EP1740557A1 EP 1740557 A1 EP1740557 A1 EP 1740557A1 EP 05716548 A EP05716548 A EP 05716548A EP 05716548 A EP05716548 A EP 05716548A EP 1740557 A1 EP1740557 A1 EP 1740557A1
Authority
EP
European Patent Office
Prior art keywords
amino
alkyl
halogen
optionally substituted
mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05716548A
Other languages
German (de)
English (en)
Inventor
Hiroshi Fujishima
Muneto Mogi
Hiroaki Yuasa
Masaomi Taijimi
Noriyuki Yamamoto
Fumihiko Hayashi
Yasuhiro Tsukimi
Jang Gupta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Priority to EP05716548A priority Critical patent/EP1740557A1/fr
Publication of EP1740557A1 publication Critical patent/EP1740557A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2

Abstract

L'invention concerne des dérivés d'urée de formule générale (I) et des sels de ceux-ci qui sont utiles en tant qu'ingrédients actifs de préparations pharmaceutiques. Les dérivés d'urée de l'invention présente une excellente activité en tant qu'antagonistes du VR1 et sont utiles pour la prophylaxie et le traitement de maladies associées à l'activité du VR1, en particulier pour le traitement de troubles ou de maladies urologiques, de type hyperactivité vésicale (vessie hyperactive), incontinence urinaire, hyperactivité vésicale neurogène (hyperflexion vésicale), hyperactivité idiopathique (instabilité vésicale), hyperplasie prostatique bénigne, et symptômes des voies urinaires inférieures ; douleurs chroniques, douleurs neuropathiques, douleurs post-opératoires, douleurs dues à une polyarthrite rhumatoïde, névralgie, neuropathies, algésie, lésion nerveuse, ischémie, neurodégénération, accident vasculaire cérébral ; maladies respiratoires et troubles inflammatoires de type asthme, bronchopneumopathie chronique obstructive (COPD), rhume, toux, éternuements, bronchite de type aiguë et chronique, bronchiolite, rhinite, rhinite allergique, rhinite vasomotrice, mucosite, sinusite, allergie, troubles associés à des irritants exogènes de type fumée de tabac, brouillard de fumée, niveaux élevés de SO2 atmosphérique et de gaz nocifs sur le lieu de travail, hyperactivité des voies aériennes, intolérance aux produits laitiers, syndrome de Löffler, emphysème, mucoviscidose, bronchectasie, fibrose pulmonaire, pneumoconiose, collagénose avec manifestations vasculaires, maladie granulomateuse, laryngite, pharyngite, pneumonie, pleurésie, asthme persistent et bronchite asthmatique chronique. Dans ladite formule (I), n représente 0, 1, 2, 3, ou 4 ; X représente O, CH2, S, or N(R10) ; R10 représentant hydrogène ou C1-6 alkyle.
EP05716548A 2004-04-20 2005-04-07 Derives d'uree utilises en tant qu'antagonistes du recepteur vanilloide (vr1) Withdrawn EP1740557A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05716548A EP1740557A1 (fr) 2004-04-20 2005-04-07 Derives d'uree utilises en tant qu'antagonistes du recepteur vanilloide (vr1)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04009274 2004-04-20
PCT/EP2005/003632 WO2005103018A1 (fr) 2004-04-20 2005-04-07 Derives d'uree utilises en tant qu'antagonistes du recepteur vanilloide (vr1)
EP05716548A EP1740557A1 (fr) 2004-04-20 2005-04-07 Derives d'uree utilises en tant qu'antagonistes du recepteur vanilloide (vr1)

Publications (1)

Publication Number Publication Date
EP1740557A1 true EP1740557A1 (fr) 2007-01-10

Family

ID=34963016

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05716548A Withdrawn EP1740557A1 (fr) 2004-04-20 2005-04-07 Derives d'uree utilises en tant qu'antagonistes du recepteur vanilloide (vr1)

Country Status (4)

Country Link
EP (1) EP1740557A1 (fr)
JP (1) JP2007533673A (fr)
CA (1) CA2563494A1 (fr)
WO (1) WO2005103018A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030417A1 (es) 2001-09-13 2003-08-06 Smithkline Beecham Plc Derivados de urea como antagonistas del receptor vainilloide
BRPI0513286A (pt) 2004-07-15 2008-05-06 Japan Tobacco Inc compostos de benzamida condensada e inibidores de atividade de receptor vanilóide subtipo (vr1), suas composições farmacêuticas, pacote comercial, fármaco e respectivos usos
TWI423819B (zh) * 2005-12-22 2014-01-21 Hydra Biosciences Inc 用於調節ｔｒｐａ１功能之化合物
CA2632508A1 (fr) * 2005-12-28 2008-06-05 Japan Tobacco Inc. Compose de 3,4-dihydrobenzoxazine et inhibiteur de l'activite du recepteur de vanilloide de type 1 (vr1)
US7906508B2 (en) 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
EP2058305A4 (fr) 2006-08-30 2010-09-22 Shionogi & Co Dérivés d'urée
WO2010026129A1 (fr) * 2008-09-02 2010-03-11 Glaxo Group Limited Antagoniste sb-705498 du récepteur trpvl pour le traitement de la rhinite
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
EP2377850A1 (fr) * 2010-03-30 2011-10-19 Pharmeste S.r.l. Antagonistes de récepteur vanilloïde TRPV1 avec portion bicyclique
CN102532016B (zh) * 2011-11-16 2013-09-18 西南大学 5-氨基喹啉-2（1h）酮类化合物及其合成方法和用途
BR112015002912B1 (pt) * 2012-08-17 2020-02-04 Basf Se processo de produção de benzoxazinonas
CN109836423B (zh) * 2019-04-03 2020-04-10 黑龙江中医药大学 一类预防或治疗肺纤维化疾病的新化合物、制备方法及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003241453A1 (en) * 2002-05-17 2003-12-02 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005103018A1 *

Also Published As

Publication number Publication date
JP2007533673A (ja) 2007-11-22
WO2005103018A1 (fr) 2005-11-03
CA2563494A1 (fr) 2005-11-03

Similar Documents

Publication Publication Date Title
EP1740557A1 (fr) Derives d'uree utilises en tant qu'antagonistes du recepteur vanilloide (vr1)
EP1670761B1 (fr) Tetrahydro-naphtalene et derives d'uree
US8088826B2 (en) Tetrahydro-naphthalene derivatives
US20090209514A1 (en) Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists
US20100137361A1 (en) Tetrahydro-Quinolinylurea Derivatives
JP2003192673A (ja) ピペラジンカルボキシアミド誘導体
EP1687262B1 (fr) Derives bicycliques d'amide, de carbamate ou d'uree en tant que modulateurs du recepteur vanilloïde
EP1594836B1 (fr) Derives d'hydroxy-tetrahydro-naphtalenyluree
JP2003192660A (ja) 尿素誘導体

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GUPTA, JANG

Inventor name: YAMAMOTO, NORIYUKI

Inventor name: MOGI, MUNETO

Inventor name: TAIJIMI, MASAOMI

Inventor name: HAYASHI, FUMIHIKO

Inventor name: FUJISHIMA, HIROSHI

Inventor name: TSUKIMI, YASUHIRO

Inventor name: YUASA, HIROAKI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TSUKIMI, YASUHIRO

Inventor name: TAIJIMI, MASAOMI

Inventor name: MOGI, MUNETO

Inventor name: YAMAMOTO, NORIYUKI

Inventor name: FUJISHIMA, HIROSHI

Inventor name: HAYASHI, FUMIHIKO

Inventor name: GUPTA, JANG

Inventor name: YUASA, HIROAKI

17Q First examination report despatched

Effective date: 20070319

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070731